EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery…
ECCA and TTEC Release “Visionary Voices” Research on the Future of Contact Centre Sales in Europe